Search the Newsreel

TherapeuticsMD Inc. stock underperforms Monday when compared to competitors

TherapeuticsMD Inc. (TXMD) stock fell by 2.90% on Monday, closing at $2.01. This underperformance occurred during a generally poor trading session where both the NASDAQ Composite Index and Dow Jones Industrial Average also experienced declines. This marks the second consecutive day of losses for …

Rigetti's Expanding Commercial Base Strengthens Growth Prospects

Rigetti Computing's RGTI second-quarter 2026 results highlighted a potentially important shift in the quantum computing market, with commercial traction emerging alongside government and academic demand. While government-backed programs and research institutions remain important sources of opportunity, management noted that the company is increasingly seeing …

Freedom Broker raises Candel Therapeutics stock price target on trial progress

Freedom Broker increased its price target for Candel Therapeutics (NASDAQ:CADL) to $15.00 from $14.00, maintaining a Buy rating, due to significant progress in its clinical trials. The firm cited the start of patient enrollment in the global Phase III AURORA trial for CAN-2409 in …

EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Emergent BioSolutions Inc. (NYSE: EBS) concerning potential securities law violations. This follows Emergent's disclosure of a $191.3 million non-cash impairment charge due to competition and pricing pressures on its NARCAN product line, which …

Rigetti Computing Inc (RGTI) News, Articles, Events & Latest Updates

Denali Therapeutics (DNLI) Could Be 42% Undervalued Following Its Earnings Report

Capricor Therapeutics Soars As FDA Keeps Deramiocel Path Alive

Capricor Therapeutics (CAPR) stock surged after the FDA agreed to review an amended filing for its Duchenne muscular dystrophy drug, deramiocel, focusing on upper-limb function. Cantor Fitzgerald upgraded CAPR to Overweight with a significantly raised price target of $28. Despite no revenue and widening …

Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (CRNX) to Vertex Pharmaceuticals Incorporated (VRTX) for $85.00 per share in cash. KSF is scrutinizing whether this acquisition price and the process leading to it adequately value Crinetics Pharmaceuticals, …

Motorola Solutions Inc. stock outperforms competitors despite losses on the day

Motorola Solutions Inc. (MSI) shares fell 2.02% to $457.08 on Monday, underperforming a generally negative trading session where the S&P 500 and Dow Jones Industrial Average also saw declines. Despite the daily loss, the stock remains 7.39% below its 52-week high achieved on August …

Oppenheimer Maintains Quince Therapeutics(QNCX.US) With Buy Rating, Maintains Target Price $82

Oppenheimer has reiterated its Buy rating on Quince Therapeutics (QNCX.US), maintaining a target price of $82. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

BioLife’s Sharp Swing To Profit Might Change The Case For Investing In BioLife Solutions (BLFS)

OCUL Stock Climbs As FDA Clears Path For AXPAXLI NDA

Ocular Therapeutix Inc. (OCUL) stock climbed by 8.12% after the FDA agreed that a single successful Phase 3 SOL-1 trial, combined with safety data, is sufficient for an AXPAXLI wet AMD New Drug Application (NDA) via the 505(b)(2) pathway. The company reported a Q2 …

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Vertex Pharmaceuticals Inc. (VRTX) saw its stock rise by 1.94% to $515.55 on Monday, despite a negative overall trading session for the stock market, which saw the S&P 500 Index and Dow Jones Industrial Average fall. This increase broke a three-day losing streak for …

OCUL Stock Climbs As FDA Path And Cash Runway De‑Risk Story

REGN UPCOMING DEADLINE: Levi & Korsinsky Alerts Regeneron

Levi & Korsinsky, LLP is alerting investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) about a pending securities class action. The lawsuit alleges that Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo Study, which led to a significant stock price drop. Investors who purchased …

Pioneer Pow earnings missed by $0.09, revenue fell short of estimates

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Tenax Therapeutics (TENX)

Levi & Korsinsky, LLP is investigating potential securities law violations involving Tenax Therapeutics (TENX) after its shares dropped 84-85%. This significant decline followed the disclosure that the Phase 3 LEVEL trial of its lead drug, TNX-103, failed to meet both its primary and key …

PDF Solutions (PDFS) Is Up 6.9% After Reaffirming 20% Growth And Filing ESOP Shelf Offering

PDF Solutions (PDFS) saw its stock rise by 6.9% after reporting its Q2 2026 results, reaffirming a 20% annual revenue growth target, and filing a US$91.80 million shelf registration for an ESOP-related share offering. This combination of profitability, growth ambitions, and capital flexibility highlights …

Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Up - Should You Buy?

Fulcrum Therapeutics shuts down, reverse-merges with N.C. biotech Slate

Fulcrum Therapeutics, which previously cut 85% of its workforce after discontinuing its sickle cell disease program, is undergoing a reverse merger with North Carolina-based Slate Medicines. The merger is anticipated to finalize in the fourth quarter of the year. Fulcrum is currently located at …

Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies

By Karen Roman Fulcrum Therapeutics, Inc. (Nasdaq: FULC) said it is merging with Slate Medicines, Inc. to advance next-generation therapeutics to treat migraine and other headache disorders, with the combining company operating as Slate Medicines, Inc. and trading on Nasdaq under the ticker "SLTE." …

What's Going On With Kratos Defense Stock Monday?

Why Medexus Pharmaceuticals Inc stock is sliding today

Revolution Medicines stock hits all-time high at 208.77 USD

Revolution Medicines Inc. (RVMD) stock reached an all-time high of $208.77, currently trading at $208.48, reflecting a remarkable 468.97% increase over the past year. Despite being considered overvalued by InvestingPro analysis, the company closed Q2 with $3.9 billion in cash and investments and is …

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (AQST) for alleged corporate wrongdoing. The firm is encouraging stockholders who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to assist with the investigation. The …

Aquestive (NASDAQ: AQST) CCO's 2,714-share tax withholding detailed

Aquestive Therapeutics' Chief Commercial Officer, Sherry Korczynski, had 2,714 shares of company common stock withheld to cover tax obligations stemming from the vesting of Restricted Stock Units. The shares were valued at $4.25 each. Following this transaction, Korczynski directly holds 235,689 shares of Aquestive …

Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript

Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting

On August 6, Corvus Pharmaceuticals (NASDAQ:CRVS) held its second-quarter 2026 earnings call, and the story was almost entirely about one molecule. Soquelitinib, the company's oral ITK inhibitor, is now being tested across five different diseases at once, from a rare blood cancer to asthma. …

Fulcrum Therapeutics Target of Unusually Large Options Trading (NASDAQ:FULC)

PHAT Maintains Overweight Rating -- Price Target Lowered to $14

Barclays has maintained an "Overweight" rating for Phathom Pharmaceuticals (PHAT) but lowered its price target from $18.00 to $14.00, reflecting a cautious outlook despite the company being significantly undervalued according to GuruFocus's GF Value™. The company, which specializes in gastrointestinal treatments, faces financial health …

Ocular gains on EyePoint phase 3 wet AMD miss

[AMD Abbreviation or acronym of age-related macular degeneration - eye problem in older persons. Word AMD is on foreground near eye model with stethoscope and visual acuity test on blurry background] Shidlovski * Ocular Therapeutix (OCUL [https://seekingalpha.com/symbol/OCUL]) is up ~7% Monday following rival EyePoint's …

Emergent BioSolutions faces securities probe after $191M NARCAN impairment and $97M adjusted EBITDA report

Emergent BioSolutions is facing a securities probe by Levi & Korsinsky law firm following a reported $191.3 million non-cash impairment on its NARCAN product and a subsequent decline in its stock. The company's Q2 revenue was $234 million with $97 million in adjusted EBITDA, …

Veranda Learning Q1FY27 net profit up 471% to ₹339 crore; guides ₹670 crore revenue

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

Contineum Therapeutics (CTNM), Disc Medicine (IRON), and Recursion Pharmaceuticals (RXRX) are making PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign …

Got $200? 1 Quantum Computing ETF to Buy Right Now.

If you have $200 and want to point it at something that feels like the future, Defiance Quantum ETF (NASDAQ: QTUM) is a serious contender instead of a science project. When you buy this ETF, you're buying a basket of companies that are already …

Universal Technical Institute cuts FY2026 EBITDA outlook, shares drop sharply amid investigation.

Universal Technical Institute (UTI) has reduced its fiscal year 2026 adjusted EBITDA forecast from over $155 million to above $135 million, leading to a significant drop in its stock price. The company attributed this cut to lower-than-expected enrollment in its high-school auto and diesel …